Not recruitingRare disease

Study of TAS3351 for Patients with Advanced Non-Small Cell Lung Cancer with EGFR Mutations

Fast replyInvestigationalNo placebo

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a type of lung cancer known as non-small cell lung cancer (NSCLC) that has specific changes in the EGFR gene, particularly the C797S mutation. The study is testing a new treatment called TAS3351, which is taken as a tablet. The purpose of the study is to explore the safety and effectiveness of TAS3351 in patients with advanced stages of this type of lung cancer.

The study is divided into different phases. Initially, the study will focus on finding the safest dose of TAS3351 and determining the best schedule for taking it. After establishing the appropriate dose, the study will further explore how well the treatment works in controlling the cancer. Participants will take the medication orally, and their health will be monitored throughout the study to assess the treatment's impact.

In addition to the medication, a special test called the QIAGEN therascreen EGFR Plus RGQ PCR Kit will be used. This test helps identify specific changes in the EGFR gene, which can guide the treatment process. The study aims to provide valuable information about the potential benefits of TAS3351 for patients with this specific type of lung cancer.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

Step 1
Initial visit
Upon joining the study, an initial visit is scheduled. During this visit, a detailed explanation of the study is provided, and written informed consent is obtained.
A series of tests are conducted to confirm eligibility, including assessments of organ function and overall health status.
Step 2
Treatment phase 1
The first phase of treatment involves taking the medication TAS3351 in tablet form. The dosage and frequency are determined based on safety assessments.
Regular monitoring is conducted to evaluate safety and determine the appropriate dose for the next phase.
Step 3
Treatment phase 2
In the second phase, the effectiveness of TAS3351 is assessed. The dosage is based on findings from the first phase.
Continued monitoring includes regular health check-ups and assessments of how the cancer responds to the treatment.
Step 4
Follow-up visits
After completing the treatment phases, follow-up visits are scheduled to monitor long-term effects and overall health.
These visits help in understanding the duration of response to the treatment and any potential side effects.

Who can join the trial?

16 criteria

Provide written informed consent, which means you agree to participate in the study after being informed about all aspects of it.
Be at least 18 years old or meet the legal adult age in your country.
Have a confirmed diagnosis of locally advanced or metastatic non-small cell lung cancer (NSCLC) that cannot be removed by surgery.
Have received certain prior treatments, including no more than two lines of chemotherapy for advanced cancer.
Have a specific type of genetic change in the cancer called EGFR mutation, confirmed by a certified laboratory.
Have tumor tissue available for testing after the most recent treatment, if required.
Have measurable disease according to specific medical guidelines (optional for some participants).
Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, which means you are fully active or have some symptoms but do not need to stay in bed for more than half of the day.
Have adequate organ function, which includes:
- Enough white blood cells (absolute neutrophil count) and platelets in your blood.
- Hemoglobin levels of at least 9.0 g/dL.
- Liver enzymes (ALT and AST) within acceptable limits.
- Total bilirubin within acceptable limits, unless you have a specific condition called Gilbert’s syndrome.
- Kidney function with a creatinine clearance of at least 50 mL/min.
- Potassium levels in your blood of at least 3.0 mmol/L.
- Women who can become pregnant must have a negative pregnancy test before starting the study treatment.
- Both men and women who can have children must agree to use highly effective birth control during the study and for a period after the last dose of study treatment (6 months for women, 3 months for men).

Who cannot join the trial?

5 criteria

Patients who do not have locally advanced or metastatic non-small cell lung cancer (NSCLC) with a specific genetic change called an acquired C797S epidermal growth factor receptor (EGFR) mutation.
Patients who are not within the specified age range for the study.
Patients who are not part of the specified clinical trial groups.
Patients who are not male or female, as both genders are included in the study.
Patients who are not considered part of a vulnerable population, which means they do not need special protection or consideration in the study.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Academisch Ziekenhuis Leiden
Responsive
Leiden, The Netherlands
Hospital Universitario 12 De Octubre
Verified
Madrid, Spain
Istituto Europeo Di Oncologia S.r.l.
Responsive
Milan, Italy

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting

Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

TAS3351 is a new medication being studied for its potential to treat advanced non-small cell lung cancer, specifically in patients who have certain changes in a gene called EGFR. This medication is being tested to see if it is safe for patients to use and to find out the best dose to use in future studies. Researchers are also looking at how well it works to treat this type of lung cancer. The study is in its early stages, which means that the medication is still being tested to understand its effects and how it can help patients with this condition.

Tas3351

What is already known about the treatment

TAS3351 – TAS3351 is an investigational medication administered orally, currently being studied in clinical trials for its potential use in treating patients with advanced non-small cell lung cancer (NSCLC) that has specific genetic changes known as EGFR mutations, including the C797S mutation. This medication is in the early stages of research, with ongoing studies to determine its safety and effectiveness. TAS3351 works by targeting and inhibiting the activity of the epidermal growth factor receptor (EGFR), which is involved in the growth and spread of cancer cells. It is classified as a targeted therapy, aiming to specifically attack cancer cells with minimal impact on normal cells.

Investigated diseases

Non-Small Cell Lung Cancer (NSCLC) with C797S EGFR Mutation – Non-small cell lung cancer is a type of lung cancer that includes several subtypes, such as adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. It is characterized by the uncontrolled growth of cells in the lung tissues. The C797S mutation in the epidermal growth factor receptor (EGFR) is an acquired genetic change that can occur in NSCLC, leading to resistance to certain targeted therapies. This mutation affects the progression of the disease by altering the cancer cells' response to treatment. As the disease progresses, it can spread to other parts of the body, a process known as metastasis. The progression of NSCLC can vary, with some cases advancing more rapidly than others.